Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen: Zarxio Lawsuit 'Poor Vehicle' To Interpret BPCIA

This article was originally published in Scrip

Executive Summary

The US Supreme Court should decline Sandoz Inc.'s request to review a ruling by the US Court of Appeals for the Federal Circuit involving the Biologics Price Competition and Innovation Act (BPCIA) because the case is a "poor vehicle" for the high-court's first interpretation of the 2010 biosimilars law, Amgen Inc. argued in a new brief.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst